PRISM BioLab Co.,LTD
206A.T
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.14B
Close$
Share Statistics
| Market cap | $5.14 Billion |
|---|---|
| Enterprise Value | $3.26 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-22.82 |
| Beta | 1.4 |
| Outstanding Shares | 36,964,000 |
Return
| Return on Equity | -46.30% |
|---|---|
| Return on Assets | -35.38% |
| Return on Invested Capital | -45.27% |
Valuation & Multiples
| P/E Ratio | -5.86 |
|---|---|
| PEG | 22.16 |
| Price to Sales | 7.32 |
| Price to Book Ratio | 2.73 |
| Enterprise Value to Revenue | 4.42 |
| Enterprise Value to EBIT | -3.8 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.14 |
| Debt to Equity | 0.24 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About PRISM BioLab Co.,LTD
35 employees
CEO: Dai Takehara PRISM BioLab Co., LTD. engages in the research and development of pharmaceuticals using its proprietary drug discovery platform, PepMetics Technology. The company's technology focuses on creating peptide mimetic small molecules designed ...